Evonik expands production capacity of TEGOSOFT® MM MB to Shanghai

- Significant share of global volume for TEGOSOFT® MM MB produced in Shanghai from June 1
- Optimized global production network to better serve personal care markets in Asia Pacific
- Reduced carbon footprint through 100% renewable energy and RSPO certified material

Shanghai, China. Evonik has expanded its manufacturing capacity for the production of TEGOSOFT® MM MB (INCI: Myristyl Myristate) from 1 June 2022. By starting the manufacture of this valuable product at its Care Solutions organics plant in Shanghai, China, Evonik can better serve all global customers and improve its supply position. Increasing the manufacturing capacity for TEGOSOFT® MM MB with a second site also enables Evonik to better cater to the increasing market demand for enzymatic-produced emollient esters in the Asia Pacific. This development underlines Evonik’s consistent commitment to enhance the availability of products according to RSPO (Roundtable on Sustainable Palm Oil) mass balance supply chain, a crucial step to the path of achieving its sustainability vision.

“Asia Pacific is a strong driving force for our personal care business growth. The increased global production network promotes supply chain agility and availability of low-carbon solutions which are of great importance to our customers within the region,” says Madeline Tan, regional business director in Asia North for Evonik’s Care Solutions business line. “We are looking to further support the local personal care industry with many products and technologies to help us reach our sustainability goals.”

TEGOSOFT® MM MB, produced in Shanghai by enzymatic esterification based on 100% renewable energy, maintains the same strict product quality and properties as that produced in Evonik’s site in Duisburg, Germany, for many years. This approach delivers a significant reduction of carbon footprint in cosmetic formulations, hence its environmental impact converges with the
macro-trend in the beauty industry, where many cosmetic producers in Asia Pacific are pursuing a more ethical, environmentally friendly and sustainable portfolio with less CO₂ emissions.

Enzymatic esterification is a prime example of green chemistry process to produce emollient esters. This eco-efficient biocatalytic synthesis, which runs on renewable energy, possesses an enormous advancement in waste prevention. Furthermore, it leads to an improved and positive impact on reducing global warming by nearly 100% lower CO₂ footprint compared to conventional chemical production procedures, as evaluated by standardized Life Cycle Assessment (LCA) on Myristyl Myristate.

As one of Evonik’s two manufacturing sites worldwide adopting state-of-the-art technologies to manufacture enzymatic esters for cosmetic formulations, the Care Solutions organics plant located in Shanghai Chemical Industry Park (SCIP) has been fully reliant on renewable energy sources to support its operation since 2020.

The use of certified raw materials according to the rules set out by the RSPO Mass Balance Supply Chain Model highlights another sustainable attribute of TEGOSOFT® MM MB. Compared to non-RSPO certified feedstock, it has an improved impact on global warming with a 68% lower CO₂ footprint, allowing local cosmetic brands to meet their ambition to use certified, sustainable palm oil-based products and reduce carbon in their value chain.

As one of the first RSPO members and a founding member of the Action for Sustainable Derivatives (ASD) initiative, Evonik has been committed to a sustainable palm oil economy over years and is striving to initiate dialog across the value chain to minimize the consequences for the environment and communities.

Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions.
for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

Asia Pacific is a strong driving force of the global economy and an important source of innovation. Consequently, Evonik endeavors to further grow its business in the region. Sales reached €3.41 billion in 2021 and the company employs over 5,000 people at more than 50 production sites in Asia Pacific.

**About Nutrition & Care**
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.

**Disclaimer**
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.